Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification

Nakajo, Kosuke; Uda, Takehiro; Kawashima, Toshiyuki; Terakawa, Yuzo; Ishibashi, Keiichiro; Tsuyuguchi, Naohiro; Tanoue, Yuta; Nagahama, Atsufumi; Uda, Hiroshi; Koh, Saya; Sasaki, Tsuyoshi; Ohata, Kenji; Kanemura, Yonehiro; Goto, Takeo

doi:10.1016/j.wneu.2021.01.012

Cited by 13 publications

(20 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From July 2011 to March 2018, there were 66 adult patients and two patients under 18 years old with newly diagnosed and untreated WHO grade -glioma who underwent surgical tumor resection and preoperative 11C-methionine PET examination, as previously reported. [5] From this previous cohort, we included adult astrocytic glioma patients with IDH mutated-TERT promoter wild-type, or those with IDH wild-type in the present study. Finally, a total of 56 patients with astrocytic tumor were included in the present cohort.…”

Section: Patientsmentioning

confidence: 99%

“…An Eminence B PET scanner (Shimadzu, Kyoto, Japan) or Biograph-16 PET scanner (Siemens, Bon, Germany) was used for 11Cmethionine PET, according to previously reported procedures. [5,7] Mean and maximum lesion-to-contralateral normal brain tissue (L/N) ratios were determined by dividing the tumor standardized uptake value by the mean standardized uptake value of the normal contralateral region of the brain, as previously reported. [5] Genetic Analysis Genetic analysis was performed as previously described.…”

Section: C-methionine Petmentioning

confidence: 99%

“…[5,7] Mean and maximum lesion-to-contralateral normal brain tissue (L/N) ratios were determined by dividing the tumor standardized uptake value by the mean standardized uptake value of the normal contralateral region of the brain, as previously reported. [5] Genetic Analysis Genetic analysis was performed as previously described. [5] Genomic DNA was extracted from surgically resected tumor specimens using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) or NucleoSpin Tissue (Machery-Nagel, Duren, Germany).…”

Section: C-methionine Petmentioning

confidence: 99%

“…[5] Genetic Analysis Genetic analysis was performed as previously described. [5] Genomic DNA was extracted from surgically resected tumor specimens using the DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) or NucleoSpin Tissue (Machery-Nagel, Duren, Germany). Hotspot mutations of IDH1/2 (codon 132 of IDH1 and codon 172 of IDH2) and TERT promoter (termed C228 and C250) were examined using Sanger sequencing with a 3130xLGenetic Analyzer (Thermo Fisher Scienti c, Waltham, MA, USA) and Big-Dye® Terminator v1.1 Cycle Sequencing Kit (Thermo Fisher Scienti c, Waltham, MA, USA).…”

Section: C-methionine Petmentioning

confidence: 99%

“…[3,4] We have previously reported a positive correlation between WHO grade and accumulation of 11C-methionine among astrocytomas, but that study did no analyze the relationship with prognosis. [5] Additional analysis was thus performed in the current study. Moreover, the clinical studies investigating the relationship between molecular analysis and uptake of amino acid PET in glioma patients are sparse, and detailed prognostic analyses of associations with molecular pro les and 11C-methionine PET uptake in glioma patients have not been fully completed.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Maximum Lesion-to-contralateral Normal Brain Tissue Ration of 11C-methionine PET as a Prognostic Imaging Biomarker for Newly Diagnosed and Untreated Astrocytic Glioma

Nakajo

Uda

Kawashima

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: This study aimed whether the uptake of amino tracer positron emission tomography (PET) can be used as an additional imaging biomarker to estimate the prognosis of glioma.Methods: Participants comprised 56 adult patients with newly diagnosed and untreated World Health Organization (WHO) gradeⅡ-Ⅳ astrocytic glioma who underwent surgical excision and were evaluated by 11C-methionine PET prior to the surgical excision at Osaka City University Hospital from July 2011 to March 2018. Clinical and imaging studies were retrospectively reviewed based on medical records at our institution.Results: Preoperative Karnofsky Performance Status (KPS) only influenced progression-free survival (PFS) (hazard ratio [HR] 0.20; 95% confidence interval [CI] 0.10-0.41, p<0.0001), whereas histology (anaplastic astrocytoma: HR 5.30, 95%CI 1.23-22.8, p=0.025; glioblastoma: HR 11.52, 95%CI 2.27-58.47, p=0.0032), preoperative KPS≥80 (HR 0.23, 95%CI 0.09-0.62, p=0.004), maximum lesion-to-contralateral normal brain tissue (LN max)≥4.03 (HR 0.24, 95%CI 0.08-0.71, p=0.01), and isocitrate dehydrogenase (IDH) status (HR 14.06, 95%CI 1.81-109.2, p=0.011) were factors influencing overall survival (OS) in multivariate Cox regression. OS was shorter in patients with LN max≥ 4.03 (29.3 months) than in patients with LN max<4.03 (not reached; p=0.03). OS differed significantly between patients with IDH mutant/LN max<4.03 and patients with IDH mutant/LN max ≥4.03.Conclusions: LN max using 11C-methionine PET may be used in prognostic markers for newly identified and untreated WHO gradeⅡ-Ⅳ astrocytic glioma.

show abstract

Section: Patientsmentioning

confidence: 99%

Section: C-methionine Petmentioning

confidence: 99%